UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:
                        (Date of earliest event reported)

                                  July 14, 2017

                           UNITED CANNABIS CORPORATION
                   -------------------------------------------
               (Exact name of registrant as specified in charter)

                                    Colorado
                ------------------------------------------------
         (State or other Jurisdiction of Incorporation or Organization)


                              1600 Broadway, Suite 1600
      000-54582                    Denver, CO 80202               46-5221947
----------------------   -----------------------------------  ------------------
   (Commission File        (Address of Principal Executive       (IRS Employer
       Number)                         Offices                  Identification
                                    and Zip Code)                   Number)


                                 (303) 386-7321
                  -------------------------------------------
              (Registrant's telephone number, including area code)


                                       N/A
              ----------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant  to  Rule  14a-12(b)  under  the  Exchange
     Act  (17 CFR 240.14a-12(b))

[ ]  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01   Entry Into a Material Definitive Agreement

     On July 14, 2017, the Company acquired 95% of the outstanding  common stock
of Prana Therapeutics, Inc. for 5,761,500 shares of the Company's common stock.

     Prana is a Delaware  corporation,  incorporated  in 2012.  Prana's flagship
product  is  Epidiferphane(TM),  a  proprietary  formulation  composed  of three
botanical  extracts that has  demonstrated  efficacy at preventing  and treating
several conditions and disease indications, including:

     o    Managing  the  negative  side  effects  of  chemotherapy;

     o    Treating inflammatory diseases such as back pain and arthritis; and

     o    Reducing tumor progression.

          Negative Side Effects Of Chemotherapy
          An estimated  650,000 patients undergo  chemotherapy each year, in the
          US alone, at a cost of approximately $12 billion.  Although, there are
          several  protocols  to  minimize  the  side  effects  associated  with
          chemotherapy,  there is  currently  no protocol  that  prevents  these
          symptoms. Preclinical data have shown Epidiferphane to be effective in
          preventing Anemia (low red blood cells),  Neutropenia (low white blood
          cells),  attenuating  Chemotherapy Induced Peripheral Neuropathy,  and
          protecting  the  endogenous   neural  stem  cell  population  that  is
          associated  with  Chemofog  (memory  problems).  At least one of these
          conditions   is   experienced   by  90%  of  patients   going  through
          chemotherapy.

          Inflammatory Disease
          Approximately  150 million patients suffer from  inflammation and pain
          associated  with arthritis and  back-centric  conditions,  spending in
          excess of $30 billion on  treatments,  many of which have  significant
          side  effects.  Epidiferphane(TM),  in  combination  with  nutritional
          ketosis,  reduces levels of cytokines that  contribute to inflammatory
          diseases and in a small number of patients has been reported to reduce
          pain, morning stiffness and improve sleep.

          Brain Tumors
          There are  approximately  80,000 new brain cancer  diagnoses in the US
          each  year;  Glioblastoma,  the  most  common  type,  has  a  survival
          diagnosis of approximately 12 months. In pre-clinical  rodent testing,
          Epidiferphane(TM), in conjunction with a nutritional ketosis, has been
          shown to double the mean life expectancy,  increase the  effectiveness
          of  chemotherapy,  and  sensitize  chemotherapy  resistant  tumors  to
          standard of care drugs.

     Prana's products are not used with marijuana.

     Prana's plan of operations for the next twelve months is as follows:

     o    File two Investigational New Drug applications with the FDA;

     o    Initiate  a  clinical  trial in the  United  States to  determine  the
          ability of Epidiferphane to treat the side effects of chemotherapy;

                                       2
<PAGE>

     o    Initiate  a  clinical  trial in the  United  States to  determine  the
          ability of Epidiferphane to treat back pain;

     o    Initiate  a  clinical  trial  in  Italy  for  elderly   patients  with
          inflammatory diseases such as back pain and arthritis; and

     o    Pursue  the  granting  of its  patents  applications  in the  USA  and
          internationally.

     Prana estimates that it will need  approximately  $500K in capital over the
next twelve months.

     Prana had gross revenue of $5,593 and $2,754, respectively,  for the twelve
months ended December 31, 2016 and the six months ended June 30, 2017

Item 2.01.  Completion of Acquisition or Disposition of Assets.

     See Item 1.01 of this report.

Item 3.02.  Unregistered Sale of Equity Securities.

     See Item 1.01 of this report.

     The Company  relied upon the exemption  provided by Section  4(a)(2) of the
Securities Act of 1933 with respect to the issuance of these shares. The persons
who acquired these shares were provided full information  regarding the Company.
There was no general  solicitation in connection with the offer or sale of these
securities.  The persons who acquired  these shares  acquired them for their own
accounts.  The  certificates  representing  these  shares will bear a restricted
legend  providing  that they  cannot be sold  except  pursuant  to an  effective
registration statement or an exemption from registration.

                                       3
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      UNITED CANNABIS CORPORATION


Dated:  July 18, 2017                By: /s/ Earnest Blackmon
                                         -----------------------------
                                         Earnest Blackmon
                                         Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kitem101prana7-17.txt", "description": "FORM 8-K ITEM 1.01", "secsgml_size_bytes": 7511}]
{"company-data": {"conformed-name": "United Cannabis Corp", "cik": "0001436161", "assigned-sic": "2834", "irs-number": "261391338", "state-of-incorporation": "CO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54582", "film-number": "17973031"}, "business-address": {"street1": "1600 BROADWAY", "street2": "SUITE 1600", "city": "DENVER", "state": "CO", "zip": "80202", "phone": "(407) 432-2547"}, "mail-address": {"street1": "1600 BROADWAY", "street2": "SUITE 1600", "city": "DENVER", "state": "CO", "zip": "80202"}, "former-company": {"former-conformed-name": "MySkin, Inc.", "date-changed": "20080528"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:
                        (Date of earliest event reported)

                                  July 14, 2017

                           UNITED CANNABIS CORPORATION
                   -------------------------------------------
               (Exact name of registrant as specified in charter)

                                    Colorado
                ------------------------------------------------
         (State or other Jurisdiction of Incorporation or Organization)

                              1600 Broadway, Suite 1600
      000-54582                    Denver, CO 80202               46-5221947
----------------------   -----------------------------------  ------------------
   (Commission File        (Address of Principal Executive       (IRS Employer
       Number)                         Offices                  Identification
                                    and Zip Code)                   Number)

                                 (303) 386-7321
                  -------------------------------------------
              (Registrant's telephone number, including area code)

                                       N/A
              ----------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant  to  Rule  14a-12(b)  under  the  Exchange
     Act  (17 CFR 240.14a-12(b))

[ ]  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))
Item 1.01   Entry Into a Material Definitive Agreement

     On July 14, 2017, the Company acquired 95% of the outstanding  common stock
of Prana Therapeutics, Inc. for 5,761,500 shares of the Company's common stock.

     Prana is a Delaware  corporation,  incorporated  in 2012.  Prana's flagship
product  is  Epidiferphane(TM),  a  proprietary  formulation  composed  of three
botanical  extracts that has  demonstrated  efficacy at preventing  and treating
several conditions and disease indications, including:

     o    Managing  the  negative  side  effects  of  chemotherapy;

     o    Treating inflammatory diseases such as back pain and arthritis; and

     o    Reducing tumor progression.

          Negative Side Effects Of Chemotherapy
          An estimated  650,000 patients undergo  chemotherapy each year, in the
          US alone, at a cost of approximately $12 billion.  Although, there are
          several  protocols  to  minimize  the  side  effects  associated  with
          chemotherapy,  there is  currently  no protocol  that  prevents  these
          symptoms. Preclinical data have shown Epidiferphane to be effective in
          preventing Anemia (low red blood cells),  Neutropenia (low white blood
          cells),  attenuating  Chemotherapy Induced Peripheral Neuropathy,  and
          protecting  the  endogenous   neural  stem  cell  population  that  is
          associated  with  Chemofog  (memory  problems).  At least one of these
          conditions   is   experienced   by  90%  of  patients   going  through
          chemotherapy.

          Inflammatory Disease
          Approximately  150 million patients suffer from  inflammation and pain
          associated  with arthritis and  back-centric  conditions,  spending in
          excess of $30 billion on  treatments,  many of which have  significant
          side  effects.  Epidiferphane(TM),  in  combination  with  nutritional
          ketosis,  reduces levels of cytokines that  contribute to inflammatory
          diseases and in a small number of patients has been reported to reduce
          pain, morning stiffness and improve sleep.

          Brain Tumors
          There are  approximately  80,000 new brain cancer  diagnoses in the US
          each  year;  Glioblastoma,  the  most  common  type,  has  a  survival
          diagnosis of approximately 12 months. In pre-clinical  rodent testing,
          Epidiferphane(TM), in conjunction with a nutritional ketosis, has been
          shown to double the mean life expectancy,  increase the  effectiveness
          of  chemotherapy,  and  sensitize  chemotherapy  resistant  tumors  to
          standard of care drugs.

     Prana's products are not used with marijuana.

     Prana's plan of operations for the next twelve months is as follows:

     o    File two Investigational New Drug applications with the FDA;

     o    Initiate  a  clinical  trial in the  United  States to  determine  the
          ability of Epidiferphane to treat the side effects of chemotherapy;

                                       2
o    Initiate  a  clinical  trial in the  United  States to  determine  the
          ability of Epidiferphane to treat back pain;

     o    Initiate  a  clinical  trial  in  Italy  for  elderly   patients  with
          inflammatory diseases such as back pain and arthritis; and

     o    Pursue  the  granting  of its  patents  applications  in the  USA  and
          internationally.

     Prana estimates that it will need  approximately  $500K in capital over the
next twelve months.

     Prana had gross revenue of $5,593 and $2,754, respectively,  for the twelve
months ended December 31, 2016 and the six months ended June 30, 2017

Item 2.01.  Completion of Acquisition or Disposition of Assets.

     See Item 1.01 of this report.

Item 3.02.  Unregistered Sale of Equity Securities.

     See Item 1.01 of this report.

     The Company  relied upon the exemption  provided by Section  4(a)(2) of the
Securities Act of 1933 with respect to the issuance of these shares. The persons
who acquired these shares were provided full information  regarding the Company.
There was no general  solicitation in connection with the offer or sale of these
securities.  The persons who acquired  these shares  acquired them for their own
accounts.  The  certificates  representing  these  shares will bear a restricted
legend  providing  that they  cannot be sold  except  pursuant  to an  effective
registration statement or an exemption from registration.

                                       3
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      UNITED CANNABIS CORPORATION

Dated:  July 18, 2017                By: /s/ Earnest Blackmon
                                         -----------------------------
                                         Earnest Blackmon
                                         Chief Executive Officer